Tenax Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Tenax Therapeutics, Inc. had return on equity of -55.6%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Tenax Therapeutics, Inc.: financial ratios, annual
Fiscal year	2011Apr 2011	2012Apr 2012	2013Apr 2013	2014Apr 2014	2015Apr 2015	2016Dec 2016	2024Dec 2024	2025Dec 2025	LTMJun 2026
Net margin	>999%	<−999%	−790.6%	<−999%	<−999%	—	—	—	—
Return on equity	—	—	—	−48.2%	−18.4%	−100.3%	−32.3%	−55.6%	−61.6%
Return on assets	357.5%	−444.8%	−257.2%	−40.5%	−16.0%	−82.7%	−29.3%	−52.4%	−57.4%
R&D as % of revenue	>999%	677.0%	206.2%	>999%	>999%	—	—	—	—
SG&A as % of revenue	>999%	>999%	308.7%	>999%	>999%	—	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Health Care sector, rankings of US companies

Figures from Tenax Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tenax Therapeutics, Inc.